

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/231717448>

# Cyclocephaloside I: A Novel Cycloartane-Type Glycoside from *Astragalus microcephalus*

ARTICLE *in* JOURNAL OF NATURAL PRODUCTS · MARCH 1998

Impact Factor: 3.8 · DOI: 10.1021/np9704011

---

CITATIONS

35

---

READS

36

4 AUTHORS, INCLUDING:



**Ihsan Calis**

Near East University

**212** PUBLICATIONS **3,205** CITATIONS

SEE PROFILE



**Oliver Zerbe**

University of Zurich

**131** PUBLICATIONS **2,680** CITATIONS

SEE PROFILE

# Cyclocephaloside I: A Novel Cycloartane-Type Glycoside from *Astragalus microcephalus*

Erdal Bedir,<sup>†</sup> Ihsan Çalis,<sup>\*,†</sup> Oliver Zerbe,<sup>‡</sup> and Otto Sticher<sup>‡</sup>

Department of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, TR-06100 Ankara, Turkey, and Swiss Federal Institute of Technology (ETH) Zurich, Department of Pharmacy, CH-8057 Zurich, Switzerland

Received August 22, 1997

A novel cycloartane-type glycoside, cyclocephaloside I (**1**) was isolated from the roots of *Astragalus microcephalus* in addition to known glycosides cyclocanthoside E (**2**) and astragaloside IV (**3**). The structure of **1** was determined by spectral (IR, <sup>1</sup>H and <sup>13</sup>C NMR, and FABMS) and chemical (acetylation) methods and established as 20,25-epoxy-3β-(β-D-xylopyranosyl)oxy-6α-(β-D-glucopyranosyl)oxy-cycloartane-16β,24α-diol.

In the flora of Turkey, the genus *Astragalus* (Leguminosae) is represented by approximately 380 species, which are listed under several sections.<sup>1</sup> *Astragalus* species, growing wild in Turkey, are of economical importance. Gum tragacanth is a very well-known foodstuff and pharmaceutical emulsifier, derived from *Astragalus* species. In Turkey, *A. microcephalus* is primarily used for the production of tragacanth.<sup>2</sup> Recently, we reported the isolation of eight cycloartane saponins from *Astragalus melanophrurius* Boiss., which were found to stimulate lymphocyte transfer in vitro,<sup>3</sup> and four novel cycloartane saponins from *Astragalus oleifolius* DC.<sup>4</sup> This paper describes the isolation and structure elucidation of a novel cycloartane-type glycoside, cyclocephaloside I (**1**), in addition to known glycosides cyclocanthoside E (**2**)<sup>5</sup> and astragaloside IV (**3**)<sup>6</sup> from the roots of *A. microcephalus* Willd.

The water-soluble part of the 80% aqueous ethanolic extract of the roots of *A. microcephalus* was first fractionated on Si gel. The fraction rich in saponins was subjected to medium-pressure liquid chromatography (MPLC) using LiChroprep C-18 as stationary phase and eluting with MeOH–H<sub>2</sub>O mixtures (60–75% MeOH in H<sub>2</sub>O) to yield the compounds **1**, **2**, and **3**, respectively.


The IR spectrum of **1** showed hydroxyl absorption bands. The FABMS of **1** exhibited quasimolecular ion peaks at *m/z* 807 [M + Na]<sup>+</sup> and at *m/z* 1569 [2 M + H]<sup>+</sup>, which are compatible with the molecular formula C<sub>41</sub>H<sub>68</sub>O<sub>14</sub>. The <sup>1</sup>H NMR spectrum of **1** showed characteristic signals due to cyclopropane–methylene protons as an AX system (δ 0.16 and 0.54, AX system, *J*<sub>AX</sub> = 4.0 Hz; H<sub>2</sub>-19) and seven tertiary methyl groups. Additionally, the resonances for two anomeric protons were observed at δ 4.80 (d, *J* = 7.4 Hz) and 4.87 (d, *J* = 7.6 Hz). Thus, compound **1** was considered to be a cycloartane-type triterpene diglycoside. This observation was supported by the <sup>13</sup>C NMR spectral data of **1**. The NMR signals were analyzed by the use of COSY and TOCSY coupled with HMQC. The <sup>1</sup>H and <sup>13</sup>C NMR data supported the assignment of the sugar moieties in **1** as β-D-xylopyranose and β-D-glucopyranose.

The remaining carbon and proton resonances were consistent with C<sub>30</sub>H<sub>50</sub>O<sub>5</sub> for the aglycon moiety. This implied six saturated ring systems because there were no olefinic protons. Additional functionalities on the aglycon included four geminal methine protons on oxygen-bearing carbon atoms (H-3, H-6, H-16, and H-24). The resonances for the oxygenated carbons also indicated the presence of four oxymethine carbons (δ 88.6, 79.5, 74.0, 68.7; C-3, C-6, C-16, and C-24, respectively) and two oxygenated quaternary carbons (δ 78.9 and 75.2, C-20 and C-25, respectively). To clarify the intermolecular connectivities of the partial structures in **1** HMBC was used. By the help of this experiment, not only connectivities but also interglycosidic linkages were revealed. These data suggested the presence of the partial structure, a monohydroxypyran derivative. The carbon resonances assigned to the side chain consisting of a doublet (δ 68.7, C-24), two triplets (δ 26.3 and 26.7, C-22 and C-23, respectively), two singlets (δ 78.9 and 75.2, C-20 and C-25, respectively), and three quartets (δ 28.8, 28.6, and 28.0; C-21, C-26, and C-27, respectively). The HMBC correlations from C-17 (to Me-18 and Me-21), C-20 (to H-17 and Me-21), C-22 (to H-17 and Me-21), C-24 (to Me-26 and Me-27), and C-25 (to Me-26) confirm this proposal. On the other hand, the FABMS of **1** exhibited a common fragmentation peak at *m/z* 143 due to the side chain. Mild acetylation of **1** yielded an octaacetate, **1a**. From the FABMS of **1a**, which displayed a [M + Na]<sup>+</sup> ion at *m/z* 1143, a molecular formula of C<sub>57</sub>H<sub>84</sub>O<sub>22</sub> was proposed for **1a**. The IR of **1a** still exhibited a free OH absorption band after acetylation, together with the information from FABMS, indicating the presence of a free hydroxyl group on the sapogenol moiety. The peaks observed at *m/z* 259 and 331, corresponding to the triacetyl–xylose oxonium and the tetraacetyl–glucose oxonium ions, respectively, confirmed the terminal positions of these units. The remaining acetoxyl resonance in the <sup>1</sup>H NMR spectrum of **1a** was attributed to the sapogenol moiety. Indeed, the resonance due to the H-24 was observed at δ 4.77, showing the expected downfield shift in comparison to **1**. No downfield shifts were observed for H-3 and H-6, supporting the sites of glycosidations. Also, no downfield shift for H-16 was observed. In the COSY experiment performed with **1a**, the signal ob-

\* To whom correspondence should be addressed. Tel.: 90 312-3103545/1089. Fax: 90 312-3114777. E-mail: acalis@dominet.in.com.tr.


<sup>†</sup> Hacettepe University.

<sup>‡</sup> Swiss Federal Institute of Technology.



**Figure 1.** ROE correlations observed for compound **1**.

served at 4.60 ppm was assigned to H-16, which shows correlations to H<sub>2</sub>-15 ( $\delta$  2.06 and 1.46), H-17 ( $\delta$  1.87), and a doublet signal at  $\delta$  5.29 ( $J$  = 3.9 Hz). The latter signal was assigned to a free hydroxyl group located at C-16, showing the site of the nonacetylated secondary hydroxyl group on the sapogenol moiety. This unexpected result can be explained by the steric hindrance of the side chain forming a pyran ring. HMQC of **1a** confirmed this deduction, because the signal assigned to C(16)-OH ( $\delta$  5.28) shows no correlation to any carbon resonance. The relative stereochemistry of **1** was established based on ROE data from a 500-ms ROESY experiment. The stereochemistry of the ring fusions and at the substituents could be unambiguously determined from ROE involving diaxial (1,3) correlations. Figure 1 displays the correlations that were used to elucidate the relative stereochemistry. Consequently, the structure of **1** was established as 20,25-epoxy-3 $\beta$ -( $\beta$ -D-xylopyranosyl)oxy-6 $\alpha$ -( $\beta$ -D-glucopyranosyl)oxycycloartane-16 $\beta$ ,24 $\alpha$ -diol, for which the trivial name cyclocephaloside I is proposed.



The carbon and proton resonances for the sugar moieties of **2** were similar to those in **1**. The remaining carbon and proton resonances for **2** were consistent with C<sub>30</sub>H<sub>52</sub>O<sub>5</sub> for the aglycon moiety. In the <sup>1</sup>H NMR spectrum of **2**, one secondary and six tertiary methyl resonances were observed. Thus, **2** appeared to have an acyclic side chain. The configuration of the C-24 chiral center was determined by comparing the <sup>13</sup>C NMR spectral data of compound **2** and of cyclocanthosides A, B, C, E, and G.<sup>5</sup> The C-24 atom, having the *S*-configuration,<sup>5</sup> resonates at  $\delta$  77.1. In contrast, the C-24 atom, having the *R*-configuration, resonates at  $\delta$  80.5.<sup>7</sup> Thus, the experimental results permit the conclusion that **2** has the 24*S*-configuration, and its structure was established as cyclocanthoside E.<sup>5</sup> The <sup>1</sup>H and

<sup>13</sup>C NMR spectral data of **3** were identical with those of astragaloside IV.<sup>6</sup>

## Experimental Section

**General Experimental Procedures.** See Çalis et al.<sup>4</sup>

**Plant Material.** *A. microcephalus* Willd. was collected from Mucur-Avanos, Nevsehir, Central Anatolia, in June 1995. Voucher specimens (95-017) have been deposited at the Herbarium of the Department of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.

**Extraction and Isolation.** The air-dried, powdered roots (260 g) were extracted with 80% aqueous EtOH under reflux. The solvent was removed by rotary evaporation, yielding 30 g of extract. The H<sub>2</sub>O-soluble part of the EtOH extract (14 g) was subjected to VLC using normal-phase Si gel 60 (150 g), employing CHCl<sub>3</sub>-MeOH and CHCl<sub>3</sub>-MeOH-H<sub>2</sub>O mixtures with increasing polarity, yielding nine fractions (fractions A-I); fraction A (200 mL of CHCl<sub>3</sub>-MeOH; 90:10, 150 mg), fraction B (200 mL of CHCl<sub>3</sub>-MeOH; 87.5:12.5, 114 mg), fraction C (400 mL of CHCl<sub>3</sub>-MeOH; 80:20, 117 mg), fraction D (200 mL of CHCl<sub>3</sub>-MeOH-H<sub>2</sub>O; 80:20:1, 1143 mg), fraction E (200 mL of CHCl<sub>3</sub>-MeOH-H<sub>2</sub>O; 80:20:2, 3181 mg), fraction F (200 mL of CHCl<sub>3</sub>-MeOH-H<sub>2</sub>O; 70:30:2, 1671 mg), fraction G (200 mL of CHCl<sub>3</sub>-MeOH-H<sub>2</sub>O; 70:30:3, 1100 mg), fraction H (200 mL of CHCl<sub>3</sub>-MeOH-H<sub>2</sub>O; 60:40:3, 614 mg), and fraction I (200 mL of CHCl<sub>3</sub>-MeOH-H<sub>2</sub>O; 60:40:4, 3870 mg). An aliquot (634 mg) of fraction G was subjected to MPLC, using LiChroprep C-18 as stationary phase, and eluted with MeOH-H<sub>2</sub>O mixtures (60–75% MeOH in H<sub>2</sub>O; 200 mL 60% MeOH, 200 mL 70% MeOH, and 300 mL 75% MeOH; fraction volume 12–14 mL) to yield the compounds **1** (fractions 25–26; 33 mg), **2** (fractions 30–34; 79 mg) and **3** (fractions 36–44; 140 mg), respectively.

**Cyclocephaloside I (1):** [ $\alpha$ ]<sub>D</sub><sup>20</sup> +6.1° (*c* 0.42, MeOH); IR  $\nu_{\max}$  (KBr) 3400 (OH) cm<sup>-1</sup>; <sup>1</sup>H NMR (C<sub>5</sub>D<sub>5</sub>N, 300 MHz)  $\delta$  4.87 (1H, d,  $J$  = 7.6 Hz, H-1'), 4.86 (1H, m, H-16), 4.80 (1H, d,  $J$  = 7.4 Hz, H-1'), 4.44 (1H, dd,  $J$  = 11.4, 2.3 Hz, H<sub>a</sub>-6''), 4.35 (1H, overlapped, H<sub>a</sub>-5'), 4.33 (1H, overlapped, H<sub>b</sub>-6''), 4.22 (1H, overlapped, H-3'), 4.20 (2H, overlapped, H-4' and H-4''), 4.10 (1H, dd,  $J$  = 8.4, 8.6 Hz, H-3'), 4.00 (2H, overlapped, H-2' and H-2''), 3.88 (1H, overlapped H-5''), 3.76 (1H, dt,  $J$  = 9.5, 6.7 Hz, H-6), 3.68 (1H, overlapped, H<sub>b</sub>-5'), 3.64 (1H, br s, H-24), 3.49 (1H, dd,  $J$  = 11.4, 4.2 Hz, H-3), 3.12 (1H, m, H<sub>a</sub>-23), 2.35 (1H, m, H<sub>a</sub>-2), 2.34 (1H, m, H<sub>a</sub>-15), 2.27 (2H, m, H-7), 2.20 (1H, m, H<sub>a</sub>-22), 2.15 (1H, m, H<sub>a</sub>-11), 2.06 (1H, d,  $J$  = 7.6 Hz, H-17), 2.01 (3H, s, H<sub>3</sub>-28), 1.98 (1H, m, H<sub>b</sub>-2), 1.95 (1H, m, H-8), 1.87 (1H, d,  $J$  = 8.4 Hz, H-5), 1.86 (1H, m, H<sub>b</sub>-15), 1.82 (2H, m, H<sub>b</sub>-11, H<sub>b</sub>-22), 1.78 (1H, m, H<sub>a</sub>-12), 1.65 (1H, m, H<sub>b</sub>-12), 1.64 (3H, s, H<sub>3</sub>-18), 1.58 (1H, m, H<sub>a</sub>-1), 1.51 (3H, s, H<sub>3</sub>-21), 1.42 (3H, s, H<sub>3</sub>-26), 1.34 (3H, s, H<sub>3</sub>-29), 1.26 (3H, s, H<sub>3</sub>-27), 1.22 (1H, m, H<sub>b</sub>-23), 1.20 (1H, m, H<sub>b</sub>-1), 0.88 (3H, s, H<sub>3</sub>-30), 0.54 (1H, d,  $J$  = 4.0 Hz, H<sub>a</sub>-19), 0.16 (1H, d,  $J$  = 4.0 Hz, H<sub>b</sub>-19); <sup>13</sup>C NMR (C<sub>5</sub>D<sub>5</sub>N, 75.5 MHz)  $\delta$  107.7 (d, C-1'), 105.1 (d, C-1''), 88.6 (d, C-3), 79.5 (d, C-6), 79.2 (d, C-3'), 78.9 (s, C-20), 78.5 (d, C-3'), 78.1 (d, C-5''), 75.6 (d, C-2'), 75.6 (d, C-2''), 75.2 (s, C-25), 74.0 (d, C-16), 71.8 (d, C-4'), 71.3 (d, C-4''), 68.7 (d, C-24), 67.1 (t, C-5'),

63.1 (t, C-6''), 60.8 (d, C-17), 52.7 (d, C-5), 47.4 (t, C-15), 46.8 (s, C-14), 46.1 (d, C-8), 45.9 (s, C-13), 42.7 (s, C-4), 34.8 (t, C-7), 34.2 (t, C-12), 32.3 (t, C-1), 30.2 (t, C-2), 29.5 (t, C-19), 29.1 (s, C-10), 28.8 (q, C-21, C-28), 28.6 (q, C-26), 28.0 (q, C-27), 26.7 (t, C-22), 26.3 (t, C-23), 24.1 (t, C-11), 21.1 (s, C-9), 20.9 (q, C-18), 20.1 (q, C-30), 16.7 (q, C-29); FABMS  $m/z$   $[M + Na]^+$  807 (47).

**Cyclocanthoside E (2):** IR  $\nu_{\max}$  (KBr) 3400 (OH)  $\text{cm}^{-1}$ ;  $^1\text{H}$  and  $^{13}\text{C}$  NMR ( $^1\text{H}$  = 300 MHz;  $^{13}\text{C}$  = 75.5 MHz,  $\text{C}_5\text{D}_5\text{N}$ ) data identical to the literature.<sup>5</sup>

**Astragaloside IV (3):** IR  $\nu_{\max}$  (KBr) 3400 (OH)  $\text{cm}^{-1}$ ;  $^1\text{H}$  and  $^{13}\text{C}$  NMR ( $^1\text{H}$  = 300 MHz;  $^{13}\text{C}$  = 75.5 MHz,  $\text{C}_5\text{D}_5\text{N}$ ) data identical to the literature.<sup>6</sup>

**Acetylation of 1.** Treatment of **1** (10 mg) with  $\text{Ac}_2\text{O}$  (1 mL) and pyridine (1 mL) at room temperature overnight followed by the usual workup yielded compound **1a**.

**Cyclocephaloside I octaacetate (1a):** IR  $\nu_{\max}$  (KBr) 3435 (OH), 1755 (ester)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)  $\delta$  5.29 [1H, d,  $J$  = 3.8 Hz, C(16)–OH], 5.18 (1H, t,  $J$  = 9.1 Hz, H-3'), 5.16 (1H, t,  $J$  = 9.3 Hz, H-3''), 5.04 (1H, t,  $J$  = 9.6 Hz, H-4''), 4.97 (1H, overlapped, H-2'), 4.94 (1H, overlapped, H-1'), 4.92 (1H, overlapped, H-4'), 4.77 (1H, br s, H-24), 4.60 (1H, d,  $J$  = 7.8 Hz, H-1''), 4.60 (1H, overlapped, H-16), 4.48 (1H, d,  $J$  = 7.3 Hz, H-1'), 4.17 (2H, m, H<sub>2</sub>-6), 4.08 (1H, dd,  $J$  = 11.7, 5.3 Hz, H<sub>a</sub>-5'), 3.67 (1H, ddd,  $J$  = 9.6, 5.1, 2.6 Hz, H-5''), 3.44 (1H, dt,  $J$  = 9.5, 6.7 Hz, H-6), 3.31 (1H, dd,  $J$  = 11.7, 9.6 Hz, H<sub>b</sub>-5'), 3.09 (1H, dd,  $J$  = 11.2, 4.4 Hz, H-3), 2.36 (1H, m, H<sub>a</sub>-22), 2.20 (1H, m, H<sub>a</sub>-23), 2.06 (1H, m, H<sub>a</sub>-15), 1.96 (1H, m, H<sub>a</sub>-11), 1.92 (1H, m, H<sub>a</sub>-2), 1.78 (2H, m, H-8, H<sub>a</sub>-12), 1.75 (1H, m, H<sub>b</sub>-23), 1.67 (1H, m, H<sub>b</sub>-12), 1.66 (1H, d,  $J$  = 7.7 Hz, H-17), 1.65 (1H, m, H<sub>b</sub>-2), 1.62 (1H, overlapped, H-5), 1.56 (3H, s, H<sub>3</sub>-21), 1.52 (1H, m, H<sub>a</sub>-1), 1.48 (2H, m, H-7), 1.46 (1H, m, H<sub>b</sub>-15), 1.44 (3H, s, H<sub>3</sub>-18), 1.35 (3H, s, H<sub>3</sub>-26), 1.21 (1H, m, H<sub>b</sub>-11), 1.19 (2H, m, H<sub>b</sub>-1, H<sub>b</sub>-22), 1.14 (3H, s, H<sub>3</sub>-27), 0.99 (3H, s, H<sub>3</sub>-28), 0.90 (3H, s, H<sub>3</sub>-30), 0.89 (3H,

s, H<sub>3</sub>-29), 0.51 (1H, d,  $J$  = 4.2 Hz, H<sub>a</sub>-19), 0.35 (1H, d,  $J$  = 4.2 Hz, H<sub>b</sub>-19), additional signals:  $\delta$  2.13, 2.11, 2.00, 1.99 (each 3H, s), 2.04, 2.03 (each 6H, s) (aliphatic acetoxy  $\times$  8);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75.5 MHz)  $\delta$  103.1 (d, C-1'), 100.9 (d, C-1''), 88.9 (d, C-3), 80.6 (d, C-6), 79.6 (s, C-20), 75.0 (s, C-25), 73.5 (d, C-3''), 73.4 (d, C-16), 72.0 (d, C-3'), 72.0 (d, C-2''), 71.9 (d, C-5''), 71.6 (d, C-2'), 71.5 (d, C-24), 69.2 (d, C-4'), 68.2 (d, C-4''), 62.4 (t, C-6''), 62.2 (t, C-5'), 60.1 (d, C-17), 51.5 (d, C-5), 47.6 (t, C-15), 46.5 (s, C-14), 46.1 (d, C-8), 46.0 (s, C-13), 41.3 (s, C-4), 34.2 (t, C-12), 34.1 (t, C-7), 31.5 (t, C-1), 29.9 (t, C-19), 29.0 (t, C-2), 28.8 (s, C-10), 27.7 (q, C-26), 27.5 (q, C-27), 27.5 (q, C-28), 27.5 (q, C-21), 26.5 (t, C-22), 26.0 (t, C-11), 20.8 (s, C-9), 20.6 (t, C-23), 20.0 (q, C-18), 20.0 (q, C-30), 16.1 (q, C-29); additional signals 170.7–169.2 ( $\text{COCH}_3$ ), 20.95–20.57 ( $\text{COCH}_3$ ); FABMS  $m/z$  1143 (100)  $[M + Na]^+$  (calcd for  $\text{C}_{57}\text{H}_{84}\text{O}_{22}$ ), 331 (13) [tetraacetyl–glucose oxonium] $^+$ , 259 (17) [tetraacetyl–xylose oxonium] $^+$ .

**Acknowledgment.** This study was supported by The Scientific and Technical Research Council of Turkey (TUBITAK) (project no. SBAG 1688).

## References and Notes

- (1) Davis, P. H. *Flora of Turkey and East Aegean Islands*; University Press: Edinburgh, 1970; Vol. 4, pp 49–254.
- (2) Dogan, M.; Ekim, T.; Anderson, M. W. 1985 *Biol. Agric. Hortic.* **1985**, 2, 329–334.
- (3) Çalis, I.; Yürüker, A.; Tasdemir, D.; Wright, A. D.; Sticher, O.; Luo, Y. D.; Pezzuto, J. M. *Planta Med.* **1997**, 63, 183–186.
- (4) Çalis, I.; Zor, M.; Saracoglu, I.; Isimer, A.; Rüegger, H. *J. Nat. Prod.* **1996**, 59, 1019–1023.
- (5) Isaev, M. I.; Imomnazarov, B. A.; Fadeev, Yu. M.; Kintya, P. A. *Khim. Prir. Soedin* **1992**, 360–367; *Chem. Nat. Compd. (Engl. Transl.)* **1992**, 315–320.
- (6) Kitagawa, I.; Wang, H. K.; Saito, M.; Takagi, A.; Yoshikawa, M. *Chem. Pharm. Bull.* **1983**, 31, 698–708.
- (7) Isaev, M. I.; Gorovits, M. B.; Abubakirov, N. K. *Khim. Prir. Soedin* **1989**, 156–175; *Chem. Nat. Compd. (Engl. Transl.)* **1989**, 131–147.

NP9704011